These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


175 related items for PubMed ID: 34022459

  • 1. R&D efficiency of leading pharmaceutical companies - A 20-year analysis.
    Schuhmacher A, Wilisch L, Kuss M, Kandelbauer A, Hinder M, Gassmann O.
    Drug Discov Today; 2021 Aug; 26(8):1784-1789. PubMed ID: 34022459
    [Abstract] [Full Text] [Related]

  • 2. Reviving an R&D pipeline: a step change in the Phase II success rate.
    Wu SS, Fernando K, Allerton C, Jansen KU, Vincent MS, Dolsten M.
    Drug Discov Today; 2021 Feb; 26(2):308-314. PubMed ID: 33129994
    [Abstract] [Full Text] [Related]

  • 3. Biotech R&D goes further afield.
    Lawrence S.
    Nat Biotechnol; 2006 Sep; 24(9):1052. PubMed ID: 16964201
    [No Abstract] [Full Text] [Related]

  • 4. The 802 million dollars fallacy.
    Hodgson J.
    Nat Biotechnol; 2004 Sep; 22(9):1076. PubMed ID: 15340464
    [No Abstract] [Full Text] [Related]

  • 5. Big Techs and startups in pharmaceutical R&D - A 2020 perspective on artificial intelligence.
    Schuhmacher A, Gatto A, Kuss M, Gassmann O, Hinder M.
    Drug Discov Today; 2021 Oct; 26(10):2226-2231. PubMed ID: 33965571
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Commentary: Reconsidering Pharmaceutical Research and Development Investments.
    Gagnon MA.
    Healthc Policy; 2023 Feb; 18(3):25-30. PubMed ID: 36917451
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Systematic risk identification and assessment using a new risk map in pharmaceutical R&D.
    Schuhmacher A, Brieke C, Gassmann O, Hinder M, Hartl D.
    Drug Discov Today; 2021 Dec; 26(12):2786-2793. PubMed ID: 34229082
    [Abstract] [Full Text] [Related]

  • 11. The productivity crisis in pharmaceutical R&D.
    Pammolli F, Magazzini L, Riccaboni M.
    Nat Rev Drug Discov; 2011 Jun; 10(6):428-38. PubMed ID: 21629293
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Bugs or drugs, tortoises or hares?
    Jacobs T.
    Nat Biotechnol; 2005 Mar; 23(3):293. PubMed ID: 15765079
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. China's biotech experiments.
    Hepeng J.
    Nat Biotechnol; 2005 Dec; 23(12):1472-3. PubMed ID: 16421994
    [No Abstract] [Full Text] [Related]

  • 17. Patentees research and development expenditure in Canada.
    Li S, Tomalin A.
    J Pharm Pharm Sci; 2002 Dec; 5(1):5-11. PubMed ID: 12042113
    [Abstract] [Full Text] [Related]

  • 18. Analysis of pharma R&D productivity - a new perspective needed.
    Schuhmacher A, Hinder M, von Stegmann Und Stein A, Hartl D, Gassmann O.
    Drug Discov Today; 2023 Oct; 28(10):103726. PubMed ID: 37506762
    [Abstract] [Full Text] [Related]

  • 19. Comprehensive measurement of biopharmaceutical R&D investment.
    Chandra A, Drum J, Daly M, Mirsberger H, Spare S, Neumann U, Martin S, Kirson N.
    Nat Rev Drug Discov; 2024 Sep; 23(9):652-653. PubMed ID: 39107578
    [No Abstract] [Full Text] [Related]

  • 20. Analyses of direct and indirect impacts of a positive list system on pharmaceutical R&D investments.
    Han E, Kim TH, Jeung MJ, Lee EK.
    Clin Ther; 2013 Jul; 35(7):941-9. PubMed ID: 23806327
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 9.